Abaco Capital (OXP)

 

OXP Share PerformanceMore

52 week high0.0000
52 week low0.0000
52 week change 0.0000 (0.00%)
4 week volume0 28/01/18
price0.0000
price date
close0.0000

Media for (OXP)

Presenter: Marcelo Bravo
25/01/2017
Presenter: Marcelo Bravo
12/09/2016

Latest NewsMore

Oxford Pharmascience completes demerger

Oxford Pharmascience Group confirmed that it has completed the Demerger, under which certain operating and other as...

Completion of Demerger

RNS Number: 0617A Oxford Pharmascience Group PLC 21 December 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company" and, together with its subsidiaries, the " Group") Completion of Demerger, Board Changes & Change of Company Name to Abaco Capital plc Unless otherwise indicated, capitalised terms in this announcement ha...

Confirmation of Capital Reductions

RNS Number: 8390Z Oxford Pharmascience Group PLC 19 December 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") Confirmation of Capital Reductions Unless otherwise indicated, capitalised terms in this announcement have the meaning given to them in the definitions appearing in the circular issued by the Company on 10 N...

Oxford Pharmascience completes capital subdivision

Oxford Pharmascience Group said it has now completed the subdivision of its capital whereby each Existing Share of 0.00...

Subdivision of Capital

RNS Number: 3192Y Oxford Pharmascience Group PLC 04 December 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") Subdivision of Capital Oxford Pharmascience Group plc (AIM: OXP) announces that, as contemplated in the Circular to Shareholders issued by the Company on 10 November 2017 and pursuant to the resolution...

Oxford Pharmascience gets FDA advice

Oxford Pharmascience has received scientific advice from the Federal Drug Administration regarding the development pr...

FDA Advice on OXPzero Ibuprofen OTC Opportunity

RNS Number: 7843X Oxford Pharmascience Group PLC 29 November 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") FDA Pre-IND Advice on OXPzero Ibuprofen OTC Opportunity Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today ann...

All resolutions passed at GM of Oxford Pharmascience

Oxford Pharmascience Group has confirmed that all resolutions were passed by shareholders at today's General Meeting. T...

Latest discussion posts More

  • Re: At least 18 months

    That seems logical, I will hold on in the HOPE it passes 2p and take a small profit, if not, leave for 2 or 3 years and most probably have this same conversation again.
    3-Apr-2017
    Hyperproject
  • Re: At least 18 months

    I've bailed after a big hit! The way I read it, they have no product. If they want to release it as planned then they need more trials which could cost millions and also, ...
    2-Apr-2017
    high blood pressure1
  • At least 18 months

    I have committed today at 1.7p, my first investment ever in anything outside the FT250. From my understanding of this sector, I don't expect much movement either up or down for ...
    31-Mar-2017
    Hyperproject

Users' HoldingsMore

Users who hold Abaco Capital also hold..

Codes & Symbols

ISINGB00B3LXPB43
SymbolsOXP, LSE:OXP, OXP.L, OXP:LN, LON:OXP, XLON:OXP

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account